Serum amyloid a is a marker for pulmonary involvement in systemic sclerosis

PLoS ONE

Volumn 10, Issue 1, 2015, Pages

  Lakota, Katja ^a,b   Carns, Mary ^b   Podlusky, Sofia ^b   Mrak Poljsak, Katjusa ^a   Hinchcliff, Monique ^b   Lee, Jungwha ^b   Tomsic, Matija ^a   Sodin Semrl, Snezna ^a,c   Varga, John ^b  

^a UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^b NORTHWESTERN UNIVERSITY   (United States)

^c UNIVERSITY OF PRIMORSKA   (Slovenia)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON MONOXIDE; INTERLEUKIN 6; INTERLEUKIN 8; SERUM AMYLOID A; BIOLOGICAL MARKER; C REACTIVE PROTEIN;

ADULT; ARTICLE; BLOOD LEVEL; CLINICAL FEATURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DISEASE MARKER; DYSPNEA; FEMALE; FORCED VITAL CAPACITY; HUMAN; IN VITRO STUDY; INTERSTITIAL LUNG DISEASE; LUNG DIFFUSION CAPACITY; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MOLECULAR DYNAMICS; OUTCOME ASSESSMENT; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; SCORING SYSTEM; SYSTEMIC SCLEROSIS; BLOOD; CASE CONTROL STUDY; ERYTHROCYTE SEDIMENTATION RATE; FIBROBLAST; LUNG; LUNG FUNCTION TEST; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; SCLERODERMA, SYSTEMIC; SELF REPORT;

BIOMARKERS; BLOOD SEDIMENTATION; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; FIBROBLASTS; HUMANS; INTERLEUKIN-6; LUNG; PATIENT OUTCOME ASSESSMENT; RESPIRATORY FUNCTION TESTS; SCLERODERMA, SYSTEMIC; SELF REPORT; SERUM AMYLOID A PROTEIN;

EID: 84961291431     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0110820     Document Type: Article

References (56)

1. Bhattacharyya S, Wei J, Tourtellotte WG, Hinchcliff M, Gottardi CG, et al. (2012) Fibrosis in systemic sclerosis: common and unique pathobiology. Fibrogenesis Tissue Repair 5 Suppl 1: S18.
2. Steen VD, Medsger TA (2007) Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis 66: 940-944. PMID: 17329309
3. Kraling BM, Maul GG, Jimenez SA (1995) Mononuclear cellular infiltrates in clinically involved skin from patients with systemic sclerosis of recent onset predominantly consist of monocytes/macrophages. Pathobiology 63: 48-56. PMID: 7546275
4. Strange C, Bolster MB, Roth MD, Silver RM, Theodore A, et al. (2008) Bronchoalveolar lavage and response to cyclophosphamide in scleroderma interstitial lung disease. Am J Respir Crit Care Med 177: 91-98. PMID: 17901414
5. Yilmaz N, Abul Y, Bicakcigil M, Golabi P, Celikel C, et al. (2012) Induced sputum as a method for detection of systemic sclerosis-related interstitial lung disease. Rheumatol Int 32: 1921-1925. doi: 10.1007/s00296-011-1872-4 PMID: 21448645
6. Liu X, Mayes MD, Tan FK, Wu M, Reveille JD, et al. (2013) Correlation of interferon-inducible chemokine plasma levels with disease severity in systemic sclerosis. Arthritis Rheum 65: 226-235. doi: 10.1002/art.37742 PMID: 23055137
7. Muangchan C, Harding S, Khimdas S, Bonner A, Baron M, et al. (2012) Association of C-reactive protein with high disease activity in systemic sclerosis: results from the Canadian Scleroderma Research Group. Arthritis Care Res (Hoboken) 64: 1405-1414. doi: 10.1002/acr.21716 PMID: 22556030
8. Lakota K, Mrak-Poljsak K, Rozman B, Sodin-Semrl S (2010) Serum Amyloid A and Its Potential Physiological / Pathological Functions - an Overview of Patents. Recent Patents on Endocrine, Metabolic & Immune Drug Discovery 4: 89-99. doi: 10.4155/ppa.12.26 PMID: 24397782
9. Gabay C, Kushner I (1999) Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 340: 448-454. PMID: 9971870
10. Hagihara K, Nishikawa T, Matsumura A, Song J, Tanaka T, et al. (2006) Analysis of cytokine-driven serum amyloid A expression based on the clinical results of IL-6 blocking therapy: a new cis-acting mechanism of STAT3. Inflammation and regeneration 26: 453-459.
11. Bozinovski S, Uddin M, Vlahos R, Thompson M, McQualter JL, et al. (2012) Serum amyloid A opposes lipoxin A(4) to mediate glucocorticoid refractory lung inflammation in chronic obstructive pulmonary disease. Proc Natl Acad Sci U S A 109: 935-940. doi: 10.1073/pnas.1109382109 PMID: 22215599
12. Chen ES, Song Z, Willett MH, Heine S, Yung RC, et al. (2010) Serum amyloid A regulates granulomatous inflammation in sarcoidosis through Toll-like receptor-2. Am J Respir Crit Care Med 181: 360-373. doi: 10.1164/rccm.200905-0696OC PMID: 19910611
13. Reigstad CS, Lunden GO, Felin J, Backhed F (2009) Regulation of serum amyloid A3 (SAA3) in mouse colonic epithelium and adipose tissue by the intestinal microbiota. PLoS One 4: e5842. doi: 10.1371/journal.pone.0005842 PMID: 19513118
14. Lopez-Campos JL, Calero C, Rojano B, Lopez-Porras M, Saenz-Coronilla J, et al. (2013) C-reactive protein and serum amyloid a overexpression in lung tissues of chronic obstructive pulmonary disease patients: a case-control study. Int J Med Sci 10: 938-947. doi: 10.7150/ijms.6152 PMID: 23801879
15. Eklund KK, Niemi K, Kovanen PT (2012) Immune functions of serum amyloid A. Crit Rev Immunol 32: 335-348. PMID: 23237509
16. Shah C, Hari-Dass R, Raynes JG (2006) Serum amyloid A is an innate immune opsonin for Gram-negative bacteria. Blood 108: 1751-1757. PMID: 16735604
17. Song C, Hsu K, Yamen E, Yan W, Fock J, et al. (2009) Serum amyloid A induction of cytokines in monocytes/ macrophages and lymphocytes. Atherosclerosis 207: 374-383. doi: 10.1016/j.atherosclerosis.2009.05.007 PMID: 19535079
18. Migita K, Kawabe Y, Tominaga M, Origuchi T, Aoyagi T, et al. (1998) Serum amyloid A protein induces production of matrix metalloproteinases by human synovial fibroblasts. Lab Invest 78: 535-539. PMID: 9605178
19. Faty A, Ferre P, Commans S (2012) The acute phase protein Serum Amyloid A induces lipolysis and inflammation in human adipocytes through distinct pathways. PLoS One 7: e34031. doi: 10.1371/journal.pone.0034031 PMID: 22532826
20. Kim TH, Lee YH, Kim KH, Lee SH, Cha JY, et al. (2010) Role of lung apolipoprotein A-I in idiopathic pulmonary fibrosis: antiinflammatory and antifibrotic effect on experimental lung injury and fibrosis. Am J Respir Crit Care Med 182: 633-642. doi: 10.1164/rccm.200905-0659OC PMID: 20463180
21. Weihrauch D, Xu H, Shi Y, Wang J, Brien J, et al. (2007) Effects of D-4F on vasodilation, oxidative stress, angiostatin, myocardial inflammation, and angiogenic potential in tight-skin mice. Am J Physiol Heart Circ Physiol 293: H1432-1441. PMID: 17496220
22. Tolle M, Huang T, Schuchardt M, Jankowski V, Prufer N, et al. (2012) High-density lipoprotein loses its anti-inflammatory capacity by accumulation of pro-inflammatory-serum amyloid A. Cardiovasc Res 94: 154-162. doi: 10.1093/cvr/cvs089 PMID: 22328092
23. Yang RZ, Lee MJ, Hu H, Pollin TI, Ryan AS, et al. (2006) Acute-phase serum amyloid A: an inflammatory adipokine and potential link between obesity and its metabolic complications. PLoS Med 3: e287. PMID: 16737350
24. Fasshauer M, Klein J, Kralisch S, Klier M, Lossner U, et al. (2004) Serum amyloid A3 expression is stimulated by dexamethasone and interleukin-6 in 3T3-L1 adipocytes. J Endocrinol 183: 561-567. PMID: 15590982
25. Thorn CF, Lu ZY, Whitehead AS (2004) Regulation of the human acute phase serum amyloid A genes by tumour necrosis factor-alpha, interleukin-6 and glucocorticoids in hepatic and epithelial cell lines. Scand J Immunol 59: 152-158. PMID: 14871291
26. Connolly M, Marrelli A, Blades M, McCormick J, Maderna P, et al. (2010) Acute serum amyloid A induces migration, angiogenesis, and inflammation in synovial cells in vitro and in a human rheumatoid arthritis/SCID mouse chimera model. J Immunol 184: 6427-6437. doi: 10.4049/jimmunol.0902941 PMID: 20435930
27. Dullaart RP, de Boer JF, Annema W, Tietge UJ (2013) The inverse relation of HDL anti-oxidative functionality with serum amyloid a is lost in metabolic syndrome subjects. Obesity (Silver Spring) 21: 361-366. doi: 10.1002/oby.20058 PMID: 23404653
28. King VL, Thompson J, Tannock LR (2011) Serum amyloid A in atherosclerosis. Curr Opin Lipidol 22: 302-307. doi: 10.1097/MOL.0b013e3283488c39 PMID: 21734573
29. Obici L, Raimondi S, Lavatelli F, Bellotti V, Merlini G (2009) Susceptibility to AA amyloidosis in rheumatic diseases: a critical overview. Arthritis Rheum 61: 1435-1440. doi: 10.1002/art.24735 PMID: 19790131
30. Wilson PG, Thompson JC, Webb NR, de Beer FC, King VL, et al. (2008) Serum amyloid A, but not C-reactive protein, stimulates vascular proteoglycan synthesis in a pro-atherogenic manner. Am J Pathol 173: 1902-1910. doi: 10.2353/ajpath.2008.080201 PMID: 18974302
31. Czirjak L, Kumanovics G, Varju C, Nagy Z, Pakozdi A, et al. (2008) Survival and causes of death in 366 Hungarian patients with systemic sclerosis. Ann Rheum Dis 67: 59-63. PMID: 17519276
32. Joven BE, Almodovar R, Carmona L, Carreira PE (2010) Survival, causes of death, and risk factors associated with mortality in Spanish systemic sclerosis patients: results from a single university hospital. Semin Arthritis Rheum 39: 285-293. doi: 10.1016/j.semarthrit.2009.06.002 PMID: 19782387
33. Minier T, Nagy Z, Balint Z, Farkas H, Radics J, et al. (2010) Construct validity evaluation of the European Scleroderma Study Group activity index, and investigation of possible new disease activity markers in systemic sclerosis. Rheumatology (Oxford) 49: 1133-1145. doi: 10.1093/rheumatology/keq022 PMID: 20236952
34. Hudson M, Steele R, Baron M (2007) Update on indices of disease activity in systemic sclerosis. Semin Arthritis Rheum 37: 93-98. PMID: 17363039
35. Liu X, Mayes MD, Pedroza C, Draeger HT, Gonzalez EB, et al. (2013) C-reactive protein predictsthe long-term progression of interstitial lung disease and survival in patients with early systemic sclerosis. Arthritis Care Res (Hoboken) 65: 1375-1380. doi: 10.1002/acr.21968 PMID: 23401350
36. Brandwein SR, Medsger TA, Skinner M, Sipe JD, Rodnan GP, et al. (1984) Serum amyloid A protein concentration in progressive systemic sclerosis (scleroderma). Ann Rheum Dis 43: 586-589. PMID: 6476917
37. Masi AT, Subcommittee For Scleroderma Criteria of the American Rheumatism Association D, Therapeutic Criteria C (1980) Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis & Rheumatism 23: 581-590. doi: 10.1016/j.imlet.2014.10.029 PMID: 25562673
38. Hinchcliff M, Fischer A, Schiopu E, Steen VD (2011) Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS): baseline characteristics and description of study population. J Rheumatol 38: 2172-2179. doi: 10.3899/jrheum.101243 PMID: 21844142
39. Beretta L, Santaniello A, Lemos A, Masciocchi M, Scorza R (2007) Validity of the Saint George's Respiratory Questionnaire in the evaluation of the health-related quality of life in patients with interstitial lung disease secondary to systemic sclerosis. Rheumatology (Oxford) 46: 296-301. PMID: 16877463
40. Hinchcliff M, Beaumont JL, Thavarajah K, Varga J, Chung A, et al. (2011) Validity of two new patient-reported outcome measures in systemic sclerosis: Patient-Reported Outcomes Measurement Information System 29-item Health Profile and Functional Assessment of Chronic Illness Therapy-Dyspnea short form. Arthritis Care Res (Hoboken) 63: 1620-1628. doi: 10.1002/acr.20591 PMID: 22034123
41. Milette K, Hudson M, Korner A, Baron M, Thombs BD (2013) Sleep disturbances in systemic sclerosis: evidence for the role of gastrointestinal symptoms, pain and pruritus. Rheumatology (Oxford) 52: 1715-1720.
42. Yeager ME, Colvin KL, Everett AD, Stenmark KR, Ivy DD (2012) Plasma proteomics of differential outcome to long-term therapy in children with idiopathic pulmonary arterial hypertension. Proteomics Clin Appl 6: 257-267. doi: 10.1002/prca.201100078 PMID: 22653875
43. Bargagli E, Magi B, Olivieri C, Bianchi N, Landi C, et al. (2011) Analysis of serum amyloid A in sarcoidosis patients. Respir Med 105: 775-780. doi: 10.1016/j.rmed.2010.12.010 PMID: 21215607
44. Lakota K, Mrak-Poljsak K, Rozman B, Kveder T, Tomsic M, et al. (2007) Serum amyloid a activation of inflammatory and adhesion molecules in human coronary artery and umbilical vein endothelial cells. European Journal of Inflammation 5: 73-81.
45. Lakota K, Mrak-Poljsak K, Bozic B, Tomsic M, Sodin-Semrl S (2013) Serum amyloid A activation of human coronary artery endothelial cells exhibits a neutrophil promoting molecular profile. Microvasc Res 90: 55-63. doi: 10.1016/j.mvr.2013.07.011 PMID: 23938271
46. Sodin-Semrl S, Spagnolo A, Mikus R, Barbaro B, Varga J, et al. (2004) Opposing regulation of interleukin-8 and NF-kappaB responses by lipoxin A4 and serum amyloid A via the common lipoxin A receptor. Int J Immunopathol Pharmacol 17: 145-156. PMID: 15171815
47. O 'Reilly S, Cant R, Ciechomska M, Finnegan J, Oakley F, et al. (2014) Serum Amyloid A (SAA) induces IL-6 in dermal fibroblasts via TLR2, IRAK4 and NF-κB. Immunology: n/a-n/a.
48. Kitaba S, Murota H, Terao M, Azukizawa H, Terabe F, et al. (2012) Blockade of interleukin-6 receptor alleviates disease in mouse model of scleroderma. Am J Pathol 180: 165-176. doi: 10.1016/j.ajpath. 2011.09.013 PMID: 22062222
49. O 'Reilly S, Ciechomska M, Cant R, Hugle T, van Laar JM (2012) Interleukin-6, its role in fibrosing conditions. Cytokine Growth Factor Rev 23: 99-107. doi: 10.1016/j.cytogfr.2012.04.003 PMID: 22561547
50. De Lauretis A, Sestini P, Pantelidis P, Hoyles R, Hansell DM, et al. (2013) Serum interleukin 6 is predictive of early functional decline and mortality in interstitial lung disease associated with systemic sclerosis. J Rheumatol 40: 435-446. doi: 10.3899/jrheum.120725 PMID: 23378460
51. Khan K, Xu S, Nihtyanova S, Derrett-Smith E, Abraham D, et al. (2012) Clinical and pathological significance of interleukin 6 overexpression in systemic sclerosis. Ann Rheum Dis 71: 1235-1242. doi: 10. 1136/annrheumdis-2011-200955 PMID: 22586157
52. Shima Y, Kuwahara Y, Murota H, Kitaba S, Kawai M, et al. (2010) The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab. Rheumatology (Oxford) 49: 2408-2412. doi: 10.1093/rheumatology/keq275 PMID: 20819796
53. Kadono T, Kikuchi K, Ihn H, Takehara K, Tamaki K (1998) Increased production of interleukin 6 and interleukin 8 in scleroderma fibroblasts. J Rheumatol 25: 296-301. PMID: 9489822
54. Gourh P, Arnett FC, Assassi S, Tan FK, Huang M, et al. (2009) Plasma cytokine profiles in systemic sclerosis: associations with autoantibody subsets and clinical manifestations. Arthritis Res Ther 11: R147. doi: 10.1186/ar2821 PMID: 19799786
55. Reitamo S, Remitz A, Varga J, Ceska M, Effenberger F, et al. (1993) Demonstration of interleukin 8 and autoantibodies to interleukin 8 in the serum of patients with systemic sclerosis and related disorders. Arch Dermatol 129: 189-193. PMID: 8434976
56. Schmidt K, Martinez-Gamboa L, Meier S, Witt C, Meisel C, et al. (2009) Bronchoalveoloar lavage fluid cytokines and chemokines as markers and predictors for the outcome of interstitial lung disease in systemic sclerosis patients. Arthritis Res Ther 11: R111. doi: 10.1186/ar2766 PMID: 19615053